This is a study of 12 weeks treatment with SLV 308 as an adjunctive treatment (treatment in addition to levodopa) for participants with advanced Parkinsonís disease (PD). The study is planned for 85 centers in 13 countries and is intended to enroll 280 participants globally, 90 of which will be in the U.S. An extension to this study is planned as a separate trial for those participants who are willing and eligible to participate.

READ MORE at PDTrials.org (http://www.pdtrials.org/front/trial_detail.php?trial_id=170)